首页> 美国卫生研究院文献>Journal of Vascular Research >Micromanaging Vascular Biology: Tiny MicroRNAs Play Big Band
【2h】

Micromanaging Vascular Biology: Tiny MicroRNAs Play Big Band

机译:微管理血管生物学:微小的MicroRNA发挥重要作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Micro-RNAs (miRNAs) are estimated to regulate 30% of the human genome primarily through translational repression. In 2005–2008, the first series of observations establishing the key significance of miRNAs in the regulation of vascular biology came from experimental studies involved in arresting miRNA biogenesis to deplete the miRNA pools of vascular tissues and cells. Dicer-dependent biogenesis of miRNA is required for blood vessel development during embryogenesis and wound healing. miRNAs regulate redox signaling in endothelial cells, a key regulator of vascular cell biology. miRNAs that regulate angiogenesis include miRNA 17–5p, cluster 17–92, 21, 27a&b, 126, 130a, 210, 221, 222, 378 and the let7 family. miRNAs also represent a new therapeutic target for the treatment of proliferative vascular diseases as well as hypertension. Evidence supporting the regulation of inducible adhesion molecules by miRNA supports a role of miRNAs in regulating vascular inflammation. Productive strategies to safely up-regulate as well as down-regulate miRNAs in vivo are in place and being tested for their value in disease intervention. Prudent targeting of non-coding genes such as miRNAs, which in turn regulates large sets of coding genes, holds promise in gene therapy. Recent developments in miRNA biology offer lucrative opportunities to manage vascular health.
机译:据估计,微小RNA(miRNA)主要通过翻译抑制来调控人类基因组的30%。在2005-2008年,第一批观察结果确定了miRNA在调节血管生物学中的关键作用,这是通过参与抑制miRNA生物发生以耗尽血管组织和细胞的miRNA库的实验研究来进行的。胚胎发生和伤口愈合过程中,血管发育需要micer依赖于切酶的生物发生。 miRNA调节内皮细胞中的氧化还原信号传导,这是血管细胞生物学的关键调节剂。调节血管生成的miRNA包括miRNA 17-5p,簇17-92、21、27a&b,126、130a,210、221、222、378和let7家族。 miRNA还代表了治疗增生性血管疾病和高血压的新治疗靶标。支持通过miRNA调节诱导粘附分子的证据支持miRNA在调节血管炎症中的作用。在体内安全上调和下调miRNA的生产策略已经到位,并正在测试其在疾病干预中的价值。谨慎地靶向非编码基因(例如miRNA),从而调节大量编码基因,在基因治疗中有望实现。 miRNA生物学的最新发展为管理血管健康提供了丰厚的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号